ID

29217

Descrição

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00611884

Link

https://clinicaltrials.gov/show/NCT00611884

Palavras-chave

Versões (1)
  1. 08/03/2018 08/03/2018 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

8 de março de 2018

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Diabetes NCT00611884

Inglês

Eligibility Diabetes NCT00611884

1 Formulários  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00611884
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
informed consent obtained before any trial-related activities. (trial-related activities are any procedure that would not have been performed during normal management of the subject.)
Descrição

Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximeum 14 days within the last 3 months)
Descrição

Non-Insulin-Dependent Diabetes Mellitus Disease length | Insulin naive

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0919936
treatment with one or two oral anti-diabetic drug (oads): metformin, sulphonylurea (su) (or other insulin secretagogue e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 months at a stable maximally tolerated dose or at least half maximally allowed dose according to the summary of product characteristics (spc) or locally approved pi
Descrição

Antidiabetics Oral Quantity | Metformin | Sulfonylurea | Insulin Releasing Pills | repaglinide | nateglinide | alpha-Glucosidase Inhibitors Dose Stable

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0025598
UMLS CUI [3]
C0038766
UMLS CUI [4,1]
C0021641
UMLS CUI [4,2]
C1283071
UMLS CUI [4,3]
C0994475
UMLS CUI [5]
C0246689
UMLS CUI [6]
C0903898
UMLS CUI [7,1]
C1299007
UMLS CUI [7,2]
C0178602
UMLS CUI [7,3]
C0205360
hba1c 7.0-11.0 % (both inclusive)
Descrição

Glucohemoglobin measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0202054
body mass index (bmi) 23-42 kg/m^2 [lb/in^2 x 703] (both inclusive)
Descrição

Body mass index

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
metformin contraindication according to local practice
Descrição

Medical contraindication Metformin

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0025598
thiazolidinedione (tzd) treatment within previous three months prior to visit 1
Descrição

Thiazolidinediones

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1257987
any systemic treatment with products which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) three months prior to randomisation
Descrição

Systemic therapy Interferes with Glucose metabolism | Systemic therapy Interferes with Lipid Metabolism | CORTICOSTEROIDS FOR SYSTEMIC USE

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0596620
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0598783
UMLS CUI [3]
C3653708
subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system (except for conditions associated with type 2 diabetes) that, in the opinion of the investigator, may confound the results of the trial or pose additional risk in administering trial drug
Descrição

Disease Clinical Significance Interferes with Research results | Disease Clinical Significance At risk Investigational New Drugs | Gastrointestinal Diseases | Lung diseases | Nervous system disorder | Disorder of the genitourinary system | Hematological Disease | Exception Condition Associated with Non-Insulin-Dependent Diabetes Mellitus

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C2826293
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C0683954
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C2826293
UMLS CUI [2,3]
C1444641
UMLS CUI [2,4]
C0013230
UMLS CUI [3]
C0017178
UMLS CUI [4]
C0024115
UMLS CUI [5]
C0027765
UMLS CUI [6]
C0080276
UMLS CUI [7]
C0018939
UMLS CUI [8,1]
C1705847
UMLS CUI [8,2]
C0348080
UMLS CUI [8,3]
C0332281
UMLS CUI [8,4]
C0011860
Voltar ao início da página

Similar models

Eligibility Diabetes NCT00611884

1 Formulários
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00611884
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
informed consent obtained before any trial-related activities. (trial-related activities are any procedure that would not have been performed during normal management of the subject.)
boolean
C0021430 (UMLS CUI [1])
Non-Insulin-Dependent Diabetes Mellitus Disease length | Insulin naive
Item
insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximeum 14 days within the last 3 months)
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0021641 (UMLS CUI [2,1])
C0919936 (UMLS CUI [2,2])
Antidiabetics Oral Quantity | Metformin | Sulfonylurea | Insulin Releasing Pills | repaglinide | nateglinide | alpha-Glucosidase Inhibitors Dose Stable
Item
treatment with one or two oral anti-diabetic drug (oads): metformin, sulphonylurea (su) (or other insulin secretagogue e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 months at a stable maximally tolerated dose or at least half maximally allowed dose according to the summary of product characteristics (spc) or locally approved pi
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0025598 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C0021641 (UMLS CUI [4,1])
C1283071 (UMLS CUI [4,2])
C0994475 (UMLS CUI [4,3])
C0246689 (UMLS CUI [5])
C0903898 (UMLS CUI [6])
C1299007 (UMLS CUI [7,1])
C0178602 (UMLS CUI [7,2])
C0205360 (UMLS CUI [7,3])
Glucohemoglobin measurement
Item
hba1c 7.0-11.0 % (both inclusive)
boolean
C0202054 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) 23-42 kg/m^2 [lb/in^2 x 703] (both inclusive)
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Metformin
Item
metformin contraindication according to local practice
boolean
C1301624 (UMLS CUI [1,1])
C0025598 (UMLS CUI [1,2])
Thiazolidinediones
Item
thiazolidinedione (tzd) treatment within previous three months prior to visit 1
boolean
C1257987 (UMLS CUI [1])
Systemic therapy Interferes with Glucose metabolism | Systemic therapy Interferes with Lipid Metabolism | CORTICOSTEROIDS FOR SYSTEMIC USE
Item
any systemic treatment with products which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) three months prior to randomisation
boolean
C1515119 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0596620 (UMLS CUI [1,3])
C1515119 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0598783 (UMLS CUI [2,3])
C3653708 (UMLS CUI [3])
Disease Clinical Significance Interferes with Research results | Disease Clinical Significance At risk Investigational New Drugs | Gastrointestinal Diseases | Lung diseases | Nervous system disorder | Disorder of the genitourinary system | Hematological Disease | Exception Condition Associated with Non-Insulin-Dependent Diabetes Mellitus
Item
subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system (except for conditions associated with type 2 diabetes) that, in the opinion of the investigator, may confound the results of the trial or pose additional risk in administering trial drug
boolean
C0012634 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0683954 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C2826293 (UMLS CUI [2,2])
C1444641 (UMLS CUI [2,3])
C0013230 (UMLS CUI [2,4])
C0017178 (UMLS CUI [3])
C0024115 (UMLS CUI [4])
C0027765 (UMLS CUI [5])
C0080276 (UMLS CUI [6])
C0018939 (UMLS CUI [7])
C1705847 (UMLS CUI [8,1])
C0348080 (UMLS CUI [8,2])
C0332281 (UMLS CUI [8,3])
C0011860 (UMLS CUI [8,4])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial